Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial

Laura Marandino, Andrea Necchi(Vita-Salute San Raffaele University), Russell W. Madison(Foundation Medicine (United States)), Alberto Martini(The University of Texas MD Anderson Cancer Center), Alessandra Alessi(Vita-Salute San Raffaele University), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Giuseppina Calareso(Fondazione IRCCS Istituto Nazionale dei Tumori), Maurizio Colecchia, Jeffrey S. Ross(Unknown), Alberto Briganti(University College London Hospitals NHS Foundation Trust)
Clinical Genitourinary Cancer
April 21, 2021
10.1016/j.clgc.2021.04.001
Cited by 16

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726